MLYS
Mineralys Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$26.71-1.40%
Price as of Jul 20, 2026
MLYS profitability
Mineralys Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- —
- EBITDA margin
- —
- EBIT margin
- —
- Net margin
- —
- Free cash flow margin
- —
Returns
- Return on equity
- -23.8%
- Return on assets
- -23.2%
- Return on invested capital
- -26.9%
- Asset turnover
- 0.00x
Cash efficiency
- Cash from operations
- -$136.4M
- Cash per share
- $7.83
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.